Enterprise Value
283.5M
Cash
316.9M
Avg Qtr Burn
-11.33M
Short % of Float
20.55%
Insider Ownership
1.44%
Institutional Own.
80.38%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JANX008 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
PSMA-TRACTr (JANX007) Details Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 1 Interim update |